NASDAQ$INTS

Intensity Therapeutics Inc · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Headline financials

EPS (adj)

-$0.11

No prior period
Net Income

-$1.89M

No prior period
Operating Income

-$1.96M

No prior period
Gross Profit

$0.00

No prior period
R&D Expense

$1.7M

No prior period

Revenue & EPS history

Intensity Therapeutics · Revenue · Quarterly

$0

Q4 2026

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 15 quarterly earnings reports

Historical avg

+0.8%

Avg return

Earnings day

-4.7%

Avg return

5 days after

+26.6%

Avg return

30 days after

40%

6 / 15 earnings

Positive

+17.3%

Q4 2023

Best reaction

-6.2%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026+4.4%-6.7%-26.9%
Q3 2025-5.8%-16.0%-8.2%
Q2 2025+7.2%+15.1%+11.9%
Q1 2025-5.8%-22.6%-38.6%
Q4 2024+0.5%-18.3%-18.7%
Q3 2024-6.2%-7.4%-39.2%
Q2 2024-4.2%-11.1%-17.1%
Q1 2024+6.7%+17.9%+27.5%
Q1 2023+6.7%+17.9%+27.5%
Q4 2023+17.3%+22.0%+12.0%
Q3 2023-4.0%-22.8%+263.2%
Q3 2022-4.0%-22.8%+263.2%
Q4 2022-0.4%-5.1%-19.0%
Q2 2023-0.4%-5.1%-19.0%
Q2 2022-0.4%-5.1%-19.0%
Q1 2022
Q4 2021
Q3 2021
Q2 2021
Q1 2021
Q4 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro